Seattle Genetics as per the name has its base in Seattle. It is a biotechnological firm whose specialization is in developing the targeted drugs for the kinds of diseases that have not encountered adequate mortality improvements for long. The success of any company has its roots on the leadership in place. Dr. Clay Siegall is not only the founder but also the CEO of the firm.
He attended The University of Maryland from which he graduated with a Bachelor of Science degree in Zoology. Additionally, he studied his Ph.D. in Genetics at George Washington University.
Since the formation of Seattle Genetics in 1998, Clay Siegall has directed the firm to realize a targeted therapy industry. By developing the first drug conjugate of a FDA-approved antibody, characterized by several approved indications, and enhancing the development of a robust pipeline entailing over twenty drugs. Together with a chain of strategic partnerships with the drug manufacturers such as Bayer, Pfizer, and Genentech.
At the time of establishment, Seattle Genetics was small. However, it is through the leadership of Dr. Siegall that it has grown significantly and currently adequate and qualified researchers regarding the field of cancer research.
Drug varieties keep increasing, and other demands often arise in the area. It is therefore for this reason that Seattle Genetics is prepared to undergo the transformation associated with authority related to drug development in the 21st century.
Clay Siegall believes that systemic chemotherapies, which is the former way of treating cancer, is getting out of use and could be forgotten soon. With the increase in efficacy and value of the targeted therapies over time, Dr. Clay Siegall have the belief that the treatment of the aged is likely to be displaced targeted drugs that are vastly more efficient and increasingly tolerable.
Clay Siegall always had interest in medicine, the technological power and the reason to overcoming diseases, intervening in the course of nature and restoration of health. His interest intensified particularly on cancer treatment in the course of his studies of zoology.
With his increased awareness of other treatments usually entailing amputation and radical surgery, he became convinced that there should be more improved ways.